Trial Profile

A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of ABX-002 for the Adjunctive Treatment of Major Depressive Disorder

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 26 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ABX-002 (Primary)
Indications Major depressive disorder
Focus Adverse reactions; Therapeutic Use
Acronyms AMPLIFY
Sponsors Autobahn Therapeutics

Most Recent Events

08 Jan 2025 According to an Autobahn Therapeutics media release, topline data from this trial is expected in the second half of 2025.
11 Oct 2024 Status changed from planning to recruiting.
16 Sep 2024 According to an Autobahn Therapeutics media release, the company has initiated this trial and expects reporting topline data in the second half of 2025.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com